Vertex Pharmaceuticals Incorporated (LON:0QZU)

Vertex Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,972	4,570	10,369	10,504	6,795	5,988
Short-Term Investments	1,411	1,546	849.2	274.5	729.9	670.7
Cash & Short-Term Investments	6,383	6,116	11,218	10,779	7,525	6,659
Cash Growth	10.13%	-45.48%	4.08%	43.24%	13.00%	74.85%
Accounts Receivable	1,894	1,609	1,563	1,442	1,137	885.4
Receivables	1,894	1,609	1,563	1,442	1,137	885.4
Inventory	1,499	1,205	738.8	460.6	353.1	280.8
Prepaid Expenses	639.9	459.2	537.6	431.6	442.1	228.6
Restricted Cash	9.8	-	-	-	5.1	0.7
Other Current Assets	2.6	206.5	86.1	121.9	98.6	79
Total Current Assets	10,428	9,596	14,144	13,235	9,561	8,133
Property, Plant & Equipment	2,649	2,585	1,453	1,456	1,424	1,284
Long-Term Investments	5,712	5,173	2,498	112.2	-	-
Goodwill	1,088	1,088	1,088	1,088	1,002	1,002
Other Intangible Assets	435.5	825.9	839.9	603.6	400	400
Long-Term Deferred Tax Assets	2,712	2,331	1,812	1,247	934.5	882.8
Long-Term Deferred Charges	-	62.6	58.9	40.2	-	-
Other Long-Term Assets	1,012	871.9	836.4	369.4	110.8	49.3
Total Assets	24,037	22,533	22,730	18,151	13,433	11,752
Accounts Payable	442.3	413	364.9	303.9	195	155.1
Accrued Expenses	3,271	2,628	2,556	2,003	1,467	1,301
Current Portion of Leases	-	92.3	83.7	89.4	80.2	52.9
Current Income Taxes Payable	-	161.1	99.5	123.3	211.3	104.2
Current Unearned Revenue	146.9	206.8	170.3	159.6	171.7	191.5
Other Current Liabilities	278.5	63.9	273.2	62.5	16.5	73
Total Current Liabilities	4,138	3,565	3,547	2,742	2,142	1,878
Long-Term Leases	1,527	1,657	724.7	810.3	887.2	889.5
Other Long-Term Liabilities	1,196	901.8	877.7	685.8	303.3	298
Total Liabilities	6,861	6,124	5,150	4,238	3,333	3,065
Common Stock	2.6	2.6	2.6	2.6	2.5	2.6
Additional Paid-In Capital	5,988	6,672	7,450	7,387	6,881	7,894
Retained Earnings	11,286	9,607	10,142	6,523	3,201	858.7
Comprehensive Income & Other	-101.1	127.8	-14.3	0.8	15.9	-68.5
Total Common Equity	17,175	16,410	17,580	13,913	10,100	8,687
Shareholders' Equity	17,175	16,410	17,580	13,913	10,100	8,687
Total Liabilities & Equity	24,037	22,533	22,730	18,151	13,433	11,752
Total Debt	1,527	1,750	808.4	899.7	967.4	942.4
Net Cash (Debt)	10,501	9,474	12,908	9,991	6,558	5,717
Net Cash Growth	13.46%	-26.60%	29.19%	52.36%	14.71%	82.34%
Net Cash Per Share	40.63	36.74	49.55	38.56	25.23	21.70
Filing Date Shares Outstanding	256.39	256.79	258.31	257.09	254.58	259.96
Total Common Shares Outstanding	256.29	256.94	257.7	257.01	254.48	259.89
Working Capital	6,290	6,032	10,597	10,493	7,419	6,256
Book Value Per Share	67.01	63.87	68.22	54.13	39.69	33.42
Tangible Book Value	15,652	14,496	15,653	12,221	8,698	7,285
Tangible Book Value Per Share	61.07	56.42	60.74	47.55	34.18	28.03
Land	-	33.1	33.1	33.1	33.1	33.1
Buildings	-	461.2	928.6	903.1	892.5	876.1
Machinery	-	1,061	911.9	788.6	701	605.3
Leasehold Improvements	-	737.6	474.6	410.9	363.5	234.6

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.